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Exchanges between the blood compartment and the surrounding tissues require a tight regulation
by the endothelial barrier. Recent reports inferred that VE-cadherin, an endothelial speciﬁc cell–cell
adhesion molecule, plays a pivotal role in the formation, maturation and remodeling of the vascular
wall. Indeed, a growing number of permeability inducing factors (PIFs) was shown to elicit signaling
mechanisms culminating in VE-cadherin destabilization and global alteration of the junctional
architecture. Conversely, anti-PIFs protect from VE-cadherin disruption and enhance cell cohesion.
These ﬁndings provide evidence on how endothelial cell–cell junctions impact the vascular network,
and change our perception about normal and aberrant angiogenesis.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.Fluids, cells, and nutrients are normally exchanged between the control, turnover, and regeneration of post-natal and adult tissues.
blood compartment and the surrounding tissues, under physiologic
conditions and depending on the vascular sites. In this dynamic
network, endothelial cells that line the vascular wall act as gate-
keepers to control the inﬁltration of blood proteins and circulating
cells to the underlying tissues. This vascular permeability contrib-
utes to normal angiogenesis, blood pressure control, as well as im-
mune responses [1]. Abnormal increase in vascular permeability is
often observed in many pathological conditions and human dis-
eases, such as tumor-induced angiogenesis, inﬂammation, macular
degeneration, allergy, and brain stroke. Plasma molecules and cells
can pass through (transcellular) or between (paracellular) endo-
thelial cells to ensure endothelial permeability. Transcellular pas-
sage requires either cell fenestration or a complex system of
transport vesicles, called vesiculo-vacuolar organelles. The paracel-
lular pathway, by contrast, mostly relies on the coordinated open-
ing and closure of endothelial cell–cell junctions. This latter
function must therefore be tightly regulated to maintain the endo-
thelial integrity.
1. Endothelial cell–cell junctions required functional
VE-cadherin adhesion
The adhesive contacts between cells underlie many morphoge-
netic processes during embryonic development as well as growthchemical Societies. Published by E
Bldg. Mechain, 3rd Floor, Rm.Formation, maintenance, and remodeling of the intercellular con-
tacts are achieved through physical and functional cooperation be-
tween two main adhesive structures: tight junctions and adherens
junctions (Fig. 1). Cadherins, which are the main constituent of the
adherens junctions, belong to a conserved family of cell–cell adhe-
sion molecules and link the plasma membrane with the intracellu-
lar actin cytoskeleton through catenin family proteins [2]. Tight
junctions form a dense ultra-structure organization, observable
by electron microscopy, which involves numerous adhesive mole-
cules, including the claudin and occludin family of tetraspan trans-
membrane proteins, the junctional adhesion molecules (JAMs), and
the intracellular adapters, namely zona occludens proteins, ZO-1
and ZO-2 [3]. Although tight junctions are often located apically
with respect to adherens junctions in epithelial cells, both junc-
tions are intermingled throughout cell–cell contact areas in endo-
thelial cells [4].
The barrier properties require the adhesive activities of VE-cad-
herin and claudin-5, which are key components of the adherens
and tight endothelial junctions, respectively (Fig. 1). Indeed, mac-
romolecule ﬂux is enhanced through claudin-5 and VE-cadherin-
deﬁcient endothelial monolayers in vitro [5,6]. In endothelial cells,
VE-cadherin is highly expressed and located at adherens junctions.
Its expression proﬁle appears early and is restricted to the
endothelial cell lineage, such that its promoter has been used to
generate transgene expression speciﬁcally in the endothelial com-
partment [7]. In addition, N-cadherin is also found at high levels in
endothelial cells but exhibits a weak clustering at the endothelial
cell–cell junctions and occupied preferentially apical locations.lsevier B.V. All rights reserved.
Fig. 1. Endothelial cell–cell junctions. Adherens and tight junctions sealed the endothelial cells through speciﬁc cell–cell adhesion molecules: VE-cadherin, junctional
adhesion molecules (JAM), claudin-5, occludin. These adhesion complexes are linked to the actin ﬁlament cytoskeleton and the vimentin intermediate ﬁlament network
through intracellular mediators: p120, a, b and c catenins (cat) and zona occludens (ZO) proteins. Endothelial cell–cell junctions can also concentrate signaling components
such as phospho-inositide 3 kinase (PI3K), vascular endothelial growth factor receptor type 2 (VEGF-R2), vascular endothelial cell-speciﬁc phospho-tyrosine phosphatase (VE-
PTP) and the angiopoietin-1 receptor, Tie2.
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vascular stabilization through heterotypic adhesion between endo-
thelial cells and pericytes [8]. Interestingly, the phenotype of
knockout mice for claudin-5 and VE-cadherin drastically differs.
While claudin-5 knockout mice develop normally but have a defec-
tive blood–brain barrier function and die shortly after birth [9], VE-
cadherin knockout mice are embryonic lethal and exhibit multiple
severe defects during developmental angiogenesis [10]. The sever-
ity of the phenotype due to VE-cadherin deﬁciency as compared to
the one observed in the absence of claudin-5 suggests a functional
hierarchy in the organization of the endothelial cell–cell junctions.
In agreement, VE-cadherin is required to prevent the disassembly
of the blood vessel walls [11], and to coordinate the passage of
macromolecules through the endothelium in vitro [5,12]. Finally,
VE-cadherin has been recently shown to directly enhance the
expression level of claudin-5 by tethering repressive transcription
factors away from the claudin-5 promoter [6]. Conversely, the ab-
sence of functional VE-cadherin is associated with loss of claudin-5
expression, suggesting that VE-cadherin adhesion might act up-
stream in the formation and maintenance of the endothelial barrier
integrity. Hence, VE-cadherin function in endothelial cells is inti-
mately linked to vascular integrity and endothelial barrier
plasticity.
2. Molecular basis for VE-cadherin adhesive function
VE-cadherin belongs to the cadherin super-family of cell–cell
adhesion molecules, which are encoded by more than 200 genes
in the human genome [13]. Among them, classical cadherins are
Ca2+-dependent, homophilic, cell to cell adhesion molecules ex-
pressed in nearly all cells within solid tissues. These molecules also
participate in cell–cell recognition, a property that confers the abil-
ity of cells to aggregate with and ultimately sort their most phys-
iologically relevant cell partners. It is generally admitted that
cadherins form a core adhesion complex that consists of a cadherin
dimer, binding through its extracellular region to another dimer of
cadherins expressed in adjacent cells, while its intracellular region
is anchored to the plasma membrane and linked to the cytoskele-
ton [14].Similarly to other typical cadherins, the VE-cadherin extracellu-
lar domain consists of ﬁve cadherin-type repeats, called EC (extra-
cellular cadherin) domains that are bound together by calcium ions
in a rod-like structure [14]. Interestingly, VE-cadherin lacks the
HAV tripeptide, localized in the EC1 repeat, which has been dis-
cussed to participate in cell–cell adhesion recognition in the case
of E- and N-cadherin-mediated contacts. By the use of puriﬁed re-
combinant proteins containing either fragments or total ECs, it was
shown that multiple EC interactions promote the formation of a
completely inter-digitated hexameric conﬁguration. Of note, this
hexameric structure might be speciﬁc for VE-cadherin, and has
been proposed to favor its membrane stability [15]. Once engaged
in homophilic interactions, the extracellular domain develops
additional forces, strengthening the adhesive contacts while
retaining the ability to associate and to dissociate rapidly in re-
sponse to dynamic changes in the cellular environment.
Classical cadherins are single-pass transmembrane proteins that
interact with a number of different cytoplasmic partners to carry
out their functions, which include cell–cell adhesion, cytoskeletal
anchoring, immediate intracellular signaling and control of gene
expression. The cadherin-associated proteins, catenins, are univer-
sally present in classical cadherin complexes [13]. In particular, b-
catenin interacts with the distal part of the cadherin cytoplasmic
domain and p120 catenin with amore proximal region. By contrast,
a-catenin does not bind directly to cadherin, but instead associates
with b-catenin, and provides a physical links to the actin cytoskel-
eton, either by directly binding to actin ﬁlaments or indirectly
through other actin-binding proteins such as vinculin, a-actinin,
and formins thus regulating actin polymerization, cross-linking
and dynamics at the cell–cell contact zones [16]. Under some con-
ditions, b-catenin could be substituted to c-catenin, which has been
suggested to associate preferentially with the vimentin network,
and therefore may provide a link between VE-cadherin-mediated
junctions and the intermediate ﬁlament cytoskeleton [4]. On the
other hand, p120 catenin seems to inﬂuence cadherin function by
a variety of mechanisms, which includes plasma membrane stabil-
ity, recycling, and cell surface targeting [17].
Therefore, disrupting the endothelial cell–cell junctions implies
to disconnect VE-cadherin intracellular domain from essential
J. Gavard / FEBS Letters 583 (2009) 1–6 3cohesive mediators, as well as weakening its extracellular homo-
philic interactions.
3. How do permeability inducing factors (PIFs) disrupt
VE-cadherin bonds?
There is a growing number of angiogenic and inﬂammatory
agents that have been shown to modulate vascular integrityTable 1
Permeability inducing factors (PIFs) and their proposed modes of action.




















LPS: lipopolysaccharide; PAK: p21-activated kinase; PKC: protein kinase C; ROS:
reactive oxygen species; TNF: tumor necrosis factor; VEGF: vascular endothelial
growth factor. Some PIFs are not listed here, such as bradykinine, as their effects
have been suggested to be speciﬁc of the endothelial cell models used.
Fig. 2. VE-cadherin adhesion controls the endothelial barrier properties. Four interconn
endothelial permeability, leading ultimately to the loss of VE-cadherin function, throug
complex destabilization, (3) mechanical and tension forces, and (4) reduction of cell surfa
Src and the biochemical routes involving the RhoA and calcium signaling axis have been
PIFs elicit signaling mechanisms hampering on Src and Rho activation, calcium signaling,
can enhance VE-cadherin cell surface exposure through Rap signaling axis. Ultimately
endothelial barrier.in vivo and barrier properties of endothelial monolayers in vitro.
These permeability inducing factors (PIFs) may vary in their mode
of actions, and dissecting their mediated signaling pathways has
been an intense ﬁeld of investigation (Table 1). Indeed, several
studies have primarily focused on PIF effects on the endothelial
cell–cell junction organization and have therefore permitted to un-
veil key molecular mechanisms involved in the endothelial barrier
plasticity. One can distinguish four interconnected biochemical
routes, elicited by PIFs leading to the loss of VE-cadherin function,
and ultimately culminating at the increase of vascular permeabil-
ity, through: (1) phosphorylation-driven VE-cadherin/catenin
complex destabilization, (2) reduction of cell surface expression
and exposure, (3) crosstalk with tight junctions, and (4) tension
and mechanical forces (Fig. 2).
Historically, phosphorylation has been early described as a
prominent mechanism by which cadherin and catenin interaction
can be modulated, either positively or negatively, and therefore
might decipher for overall adhesion forces [4]. To this regard, VE-
cadherin bears nine putative phospho-tyrosine sites, among which
Y658, Y685, and Y731 have been individually found to be impli-
cated in the barrier integrity [18,19]. Recently, serine phosphoryla-
tion on the conserved S665 residue emerged as a pivotal regulator
of VE-cadherin exposure at the plasma membrane [5]. Of note, vas-
cular endothelial growth factor (VEGF) was demonstrated to trig-
ger VE-cadherin tyrosine phosphorylation and remodeling in
endothelial cells [20]. Similarly, most of the PIFs identiﬁed so far
promote an increase in VE-cadherin tyrosine phosphorylation
and diminution of VE-cadherin/catenin binding. Although several
kinases were proposed to contribute to VE-cadherin phosphoryla-
tion, how exactly tyrosine phosphorylation promotes vascular
leakage remains elusive [4]. However, the non-receptor tyrosine
kinases of the Src family might be involved in this biological pro-
cess. Indeed, Src-deﬁcient mice show decreased vascular leakage
and VE-cadherin tyrosine phosphorylation in response to VEGFected pathways can be elicited by permeability inducing factors (PIFs) to increase
h: (1) crosstalk to tight junctions, (2) phosphorylation-driven VE-cadherin/catenin
ce expression and exposure. Essential mediators such as the kinases: Pyk2, PAK, and
shown to act downstream angiogenic and inﬂammatory PIFs. At the opposite, anti-
VE-cadherin phosphorylation, acto-myosin contractility and actin polymerization, or
, anti-PIFs can reinforce VE-cadherin adhesion and therefore the integrity of the
Table 2
Anti-permeability inducing factors (anti-PIFs) and their effects on the endothelial
barrier.
Anti-PIFs Signaling system Effects on the endothelial barrier
Angiopoietin-1 Tie-2 VE-cadherin membrane stabilization
Rho-GAP Src–Ca++ pathway inhibition
mDia Acto-myosin contractility
Robo-4 Slit-2 VE-cadherin membrane stabilization
Src inhibition
S1P S1P-R1 Rac/PAK
cAMP-GPCR Rap VE-cadherin membrane stabilization
FGF FGF-R1 VE-cadherin membrane stabilization
cAMP-GPCR: cyclic adenosine monophosphate elevating G protein-coupled recep-
tor; FGF: ﬁbroblast growth factor; GAP: GTPase activating protein; mDia: mam-
malian diaphanous; PAK: p21-activated kinase; R: receptor; S1P: sphingosine 1
phosphate.
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can efﬁciently restore the barrier integrity in a pathological context
such as brain stroke, tumor cell extrasavation, and retinal hyper-
permeability [22–24].
A reduction in VE-cadherin stability at the plasma membrane
might also contribute to compromise the endothelial barrier
integrity. Indeed, VE-cadherin cell surface expression is frequently
altered in hyper-permeability of the vascular network in patholog-
ical conditions such as inﬂammation, diabetes, and virus exposure
[29–31]. Interestingly, internalization of VE-cadherin has been
observed in response to monocyte extrasavation, inhibition of
FGF signaling and activation of VEGF-R2 by VEGF [5,25,26]. At
the molecular level, VEGF triggers the hierarchical activation of
the Src tyrosine kinase, Vav2, a guanine-nucleotide exchange factor
for the small Rho GTPase, Rac and its downstream effector the p21-
activated kinase, PAK [5]. This signaling axis culminates at the
PAK-dependent phosphorylation of VE-cadherin, on a highly con-
served serine residue, which directs VE-cadherin to endocytosis
[5]. Consistent with these results, active forms of PAK were
observed to be targeted and localized at cell–cell junctions upon
PIF exposure [27]. In addition, decreasing the association between
VE-cadherin and p120 catenin leads to clathrin-dependent VE-cad-
herin endocytosis [28]. To this regard, blocking FGF signaling in
endothelial cells triggers the dissociation between VE-cadherin
and p120, leading to the reduction of VE-cadherin exposure at
the cell surface, and the subsequent disassembly of endothelial
cell–cell junctions [26]. Ultimately, PIF dose, kinetics and mode
of action might control the fate of internalized VE-cadherin and
drive it to temporary storage compartment, recycling pathway,
or degradation.
As discussed above, crosstalk between VE-cadherin and tight
junctions is now admitted [6]. Indeed, an increase in endothelial
monolayer permeability is generally accompanied by the reorgani-
zation of junctional proteins, leading to a transient opening of the
endothelial junctions and a subsequent increase in paracellular
permeability. It has been demonstrated that not only VE-cadherin
is relocated and phosphorylated upon stimulation by diverse PIFs,
but similar observations have also been made for tight junction
components [32]. Interestingly, the diminution of VE-cadherin
plasma membrane exposure corroborates with compromised orga-
nization of the endothelial tight junctions [5,26]. As extrapolate
from epithelial cells, adherens junctions are functionally linked
tight junctions and vice versa [3]. This hypothesis has been further
demonstrated since claudin-5 mRNA is down regulated in endo-
thelial cells lacking VE-cadherin expression or in which VE-cad-
herin activity is lost [6]. Conversely, rescuing VE-cadherin
function triggers claudin-5 transcription. Hence, VE-cadherin can
directly control claudin-5 expression, and therefore the organiza-
tion and maturation of endothelial tight junctions [2,6]. At the
molecular level, VE-cadherin adhesion prevents b-catenin and
FoxO binding to claudin-5 promoter, where they could repress its
transcription. These data offer a ﬁne molecular framework on
how VE-cadherin encrypts global endothelial cell–cell junction
architecture. On the other hand, the loss of expression of the junc-
tional adhesion molecule, JAM-C, results in the stabilization of VE-
cadherin-mediated adhesion, and the subsequent decreased in ba-
sal permeability and VEGF- and histamine-induced increases in
vascular leakage [33], suggesting then a more complex bidirec-
tional interplay between adherens and tight endothelial junctions
at the cell–cell contact interface.
Finally, endothelial permeability largely depends on actomyo-
sin-based cell contractility, as intracellular actin ﬁbers exert cen-
tripetal tension on intercellular junctions [34]. Inhibition of acto-
myosin contractility by pharmacological agents, as well as exami-
nation of myosin light chain (MLC) phosphorylation status had
placed mechanical forces in the pathway by which PIFs, such asthrombin and histamine exert their effects [35]. MLC phosphoryla-
tion mainly relies on the activation of the small GTPase, RhoA,
which in turn controls the two serine/threonine kinases, ROCK,
and PRK [35–37]. Interestingly, elevation of intracellular calcium
signaling has been shown upstream RhoA activation in such bio-
chemical routes [37,38]. In addition, blocking PAK-dependent
acto-myosin contractility prevents from endothelial permeability
increased by several PIFs, such as VEGF, histamine, tumor necrosis
factor (TNFa), lipopolysaccharide from the bacterial wall (LPS), as
well as atherosclerotic risk factors [27,39].
In conclusion, coordinated disruption of VE-cadherin intracellu-
lar interactions by phosphorylation, internalization, and mechani-
cal forces most likely contributes collectively to the destabilization
and the disengagement of VE-cadherin adhesion, culminating at
the restructuration of both adherens and tight junctions and the
subsequent opening of endothelial cell–cell junctions.
4. Looking for anti-permeability inducing factor (anti-PIFs)
mechanisms
Few angiogenic mediators exert an anti-permeability action,
since plasma leakage supplies essential growth factors, matrix pro-
teins, and angiogenic factor-producing cells to the perivascular
zones. Thus, blocking vascular leakage may have direct implica-
tions in modulating angiogenesis and inﬂammation, as well as
therapeutic potentials in the treatment of many human diseases
characterized by loss of vascular integrity. In this paragraph, the
proposed mechanisms by which anti-permeability inducing factors
(anti-PIFs) exert their effects on the endothelial barrier function
will be discussed (Fig. 2). The most relevant anti-PIFs are reported
in Table 2, among them: angiopoietin-1 and its cognate receptor
Tie2, ﬁbroblast growth factor (FGF), Robo-4, cAMP-elevating G pro-
tein-coupled receptor (GPCR) agonists, and sphingosine-1-phos-
phate (S1P).
Although angiopoietin-1 and VEGF are both potent pro-angio-
genic factors, angiopoietin-1 stabilizes blood vessels and protects
from VEGF-induced vascular permeability. Indeed, angiopoietin-1
administration or overexpression in the dermal compartment can
protect from the potentially lethal actions of VEGF as a conse-
quence of uncontrolled plasma leakage [40]. In this regard, angio-
poietin-1 can potently block VEGF-induced endothelial
permeability in vitro [41], suggesting that their opposing effects
on vascular leakage may be exerted through direct stimulation of
endothelial cells. In addition, angiopoietin-1 might exert a general
anti-vascular permeability effect, protecting blood vessels from the
plasma leakage caused by thrombin and bacterial wall compo-
nents, such as LPS [41,42]. Thus, the angiopoietin-1/Tie2 endothe-
lial signaling axis might play a key anti-inﬂammatory role in
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shock. Several signaling mediators, including calcium signaling or
GTPase Activating Proteins (GAPs) for RhoA, have been proposed
to impede on the endothelial barrier disruption [42,43], but the ex-
act molecular mechanisms were still unknown. We therefore revis-
ited our ﬁndings on phospho-serine-dependent internalization of
VE-cadherin and investigated the effects of angiopoietin-1 on the
control of endothelial monolayer permeability [5]. Our data indi-
cated that angiopoietin-1 elicits a signaling pathway through
Tie2, which can compete for Src activation by VEGF-R2, therefore
halting the VEGF signaling to VE-cadherin internalization [44].
Similar Src inhibition has been recently demonstrated to oppose
to VEGF-induced vascular permeability in response to Robo-4, a li-
gand for the endothelial Slit-2 receptor [45]. Interestingly, Tie2 is
localized at cell–cell junctions in an intact endothelial monolayer,
where it contributes to stabilize VE-cadherin adhesion, in associa-
tion with the vascular endothelial phospho-tyrosine phosphatase
(VE-PTP) [46,47]. Both Tie2 localization and downstream signaling
are modiﬁed in the absence of endothelial cell–cell contacts, sug-
gesting a regulatory feedback between VE-cadherin adhesion and
Tie2 function. This ‘‘super” clustering of adhesion and signaling
receptors at the contacting zones might then preserve controlled
paracellular permeability in quiescent conditions and in response
to acute exposure to angiogenic factors.
In addition to angiopoietin-1 action, membrane stability of VE-
cadherin is also involved in the protective mechanism exerted by
FGF signaling in the vascular maintenance [26]. FGF is a pleiotropic
factor playing a protective effect on existing vasculature, primarily
thought to be mediated by anti-apoptotic signaling. However, in
contrast to VEGF that can activate pro-survival signals as well,
FGF is unable to induce vascular leakage and endothelial fenestra-
tions. Indeed, it has been recently shown that inhibition of FGF sig-
naling reduces the interaction between p120 and VE-cadherin,
while VE-cadherin internalization is enhanced [26]. Conversely,
the VE-cadherin/p120 interaction is critical to prevent from VE-
cadherin endocytosis [28], suggesting therefore that FGF signaling
might prevent from the lost of p120 binding to VE-cadherin, culmi-
nating at VE-cadherin stabilization at the plasma membrane. Final-
ly, cyclic adenosine monophosphate (cAMP)/Epac/Rap1 signaling
axis promotes a decreased paracellular permeability in response
to cAMP-elevating G protein-coupled receptor (GPCR) agonists,
such as prostaglandin E2 and atrial natriuretic peptide (ANP)
[12,48,49]. Indeed, Rap1 has been demonstrated to enhance VE-
cadherin-mediated adhesion by stabilizing the adhesion com-
plexes at the plasma membrane [12,33].
The sphingosine 1 phosphate (S1P), a bioactive lipid that binds
the endothelial S1P receptors, type 1 and 2, alternatively known as
Edg1 and Edg2, had emerged as an effective barrier-protective ago-
nist in addition to its pro-angiogenic abilities. Cytoskeletal rear-
rangement and barrier enhancement through Rac activation have
been on the other hand proposed to militate for vascular integrity
by S1P signaling [50], while reinforcement of endothelial cell/per-
icyte interaction through N-cadherin adhesion cannot be excluded
in its anti-PIF effects [8].
Thus, protection of VE-cadherin adhesion likely contributes to
anti-PIF molecular mechanisms, such as through angiopoietin-1,
FGF, and intracellular Rap signaling. Actin rearrangement and cell
adhesion collectively cooperate to the control of the endothelial
barrier properties. Screening for novel anti-PIFs has recently inten-
siﬁed as this research ﬁeld has direct implications in the quest for
therapeutic drugs designed to target aberrant vascular leakiness,
inﬂammation, and edema.
Despite fantastic progresses in our understanding of the molec-
ular mechanisms regulating VE-cadherin function in the endothe-
lial barrier, the dynamics of VE-cadherin trafﬁcking, including
endocytosis and recycling are not fully elucidated yet. Ultimately,elucidating the biochemical route by which VEGF, angiogenic fac-
tors and oncogenes modulate VE-cadherin, cell–cell junctions and
vascular integrity will help identify new therapeutic targets for
the treatment of many human diseases that exhibit aberrant vas-
cular leakage. Although anti-VEGF/VEGF-R drugs have been ap-
proved in colon cancer treatment and ocular diseases, they are
however not suitable for all patients, and can affect normal vascu-
lature and exhibit tumor recurrence upon therapy withdraw.
Hence, it will be crucial in the future to ascertain the molecular ba-
sis for the development of novel therapeutic targets designed to
promote normalization of the vascular wall and its micro-
environment.
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